Member Info for AndytheMKDon

Yesterday there was an un-crossing trade after close which pushed the closing price above the offer price, I wouldn't be surprised if there is another one today to push the closing price above 0.9p..

The PR has never been so good, believe me.. Now we just need confirmation of grant funding or license agreement. :+)

..

We know he's applied for a grant it's in the annual report, he also re-stated it in his recent presentation.. Just need Matt Han**** to throw a few dollars in our direction now.. :+) The government have allocated £1.7Bn to grant fund Covid research.

..

I suspect we all know the science and how relevant our products are to supply a piece of the jigsaw to the solution of Covid19.. We now just need something tangible from SAR management to establish we are entering into trials albeit via grant funding or being partnered by another organisation. I can't believe über conservative Tim would be continually banging the drum if he didn't eventually intend to get a tune out of it. gla. Andy. :+)

Looking at the trading pattern it looks very much like a large order is being worked in the background as despite pressure on the offer price they're not taking the price up. Once through we should see some movement imo.

JAK kinases play a key role in mediating signaling from cytokine receptors. Because of the importance of cytokines in promoting autoimmune and inflammatory diseases, the JAK kinases have received much attention as possible therapeutic targets for modulating the impact of cytokines on these diseases. TYK2 and JAK1 mediate signaling for a number of cytokines , including IL-12, IL-23, IL-6, IL-22, and IFN-a (20). In this study, we identified SAR-20347 as a small molecule inhibitor of TYK2/JAK1-dependent signaling, with nanomolar potency for TYK2/JAK1 and selectivity over JAK2 and JAK3 in both biochemical and cell-based assays. The pharmacokinetic profile of SAR-20347 was also favorable, demonstrating a moderate half-life of approximately 3 hours, with excellent bioavailability and distribution to tissues. In assays using human primary cells, SAR-20347 inhibited TYK2 and JAK1 activity as assessed by complete inhibition of IL-12 induced IFN-? production in PBMCs, reporter expression in an IFN-a responsive cell line, and pSTAT inhibition after stimulation with single cytokines (e.g, IL-12/pSTAT4, IL-6/pSTAT3). The in vitro profile of SAR-20347 suggests that it has the potential to be beneficial in diseases where cytokines utilizing TYK2 and JAK1 play a critical role. The marked preference for TYK2/JAK1 offers distinct advantages over other JAK inhibitors that can interfere with JAK2, since inhibition of JAK2 can cause some degree of unwanted myelosuppression, particularly anemia and thrombocytopenia.

BIGHOW.. Good morning. You might be onto something there with SAR-20347, I've read the article and it seems very relevant in signalling / potentially treating the main interleukins responsible for Covid. Come on Tim and John paint the picture and lets get this show on the road. gla. Andy. :+)

I’d settle for getting above 1p and holding it as a first step. ;+)

Morning everybody. All the TA is looking positive right now. Moving average, short and medium macd, and the bollinger bands are all pointing north. gla. Andy. :+)

Many thanks my friend. :+)

Many thanks for the reply. :+)
Another question and sorry if it sounds a bit rudimentary but is our Tyk2 Jak1 SDC 1801 more Tyk2 than Jak1 or are they both 100% present?? I.e. it could just as easily be referred to as a Jak1 Tyk2 ??

From the article:
Interleukin-6 (IL-6) is one of the key pro-inflammatory cytokines. Although initially identified as signalling JAK1, JAK2 and TYK2, recent studies have highlighted the essential role displayed be JAK1. IL-6 signals through the IL-6R and glycoprotein 130 (gp130) receptor, the former being expressed only on the membrane of a few cell types, while the latter ubiquitously expressed.
Help me out Fadec, am I right in assuming that JAK1 is key to signalling the pathway to IL-6??

By the way just ignore the "click here if you want to read the rest of the article" and scroll down it's all there. :+)

Good morning everybody. Picking up on the effect of TYK / JAK inhibitors effect on the IL pathways I found the following article. It seems to suggest that TYK2 doesn't directly effect the IL-6 pathway but JAK1 does and that both need to be present for signalling a response. It is looking clearer to me as I read more that whilst an antiviral will be key to combating covid it needs to be used in a combo with an autoimmune product for pathway signalling to enable the antiviral to be effective. The governments chief scientific officer clearly stated on Thursday, when asked about Remdesivir and would it be a cure for covid, "that it could be effective when most likely used in combination with other products". I'm sure the worlds scientist will be busily joining the dots the same as we are. Have a lovely weekend everyone the suns out.. :+) Andy.

https://www.researchgate.net/publication/253336263_A_Restricted_Role_for_TYK2_Catalytic_Activity_in_Human_Cytokine_Responses_Revealed_by_Novel_TYK2-Selective_Inhibitors

fearg. Do me a favour and try and spell the company name correctly, just once, there’s a good chap. :+)

Whilst Tim doesn't look a scientist he does look like a proper "pencil neck" so if anybody can get through government red tape to get us a grant my money would be on "Ol Tim the pencil neck". :+)))

Down to my last twenty of so Stella's in the beer fridge !!! :0(

Hello Rich I hope you are well. My feeling is the sells this morning were the traders and rainbow chasers off chancing their arm at VAL and a couple of others, now coming back in here. I don't think any of the wise money went anywhere. gl. Andy.